A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy
Stopped Failure of TV50717-CNS-30080 (parent study) to meet the primary efficacy endpoint
Conditions
- Cerebral Palsy, Dyskinetic
Interventions
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.